Connecticut Attorney General William Tong announced a settlement with beauty retailer Sephora resolving an investigation into the company’s marketing of anti-aging skincare products containing active ingredients like retinol to children under 13. Sephora agreed to adopt enforceable safeguards including requiring suppliers to provide age suitability warnings, disclosing those warnings on product pages, training employees to advise young customers, and maintaining a public resource on age-appropriate products. No monetary penalty was imposed.
Sephora must (1) require all skincare product suppliers to provide warnings and disclaimers about the suitability of their products for children under 13; (2) clearly and conspicuously disclose these warnings on all relevant product pages on its website; (3) train all customer-facing employees to identify products unsuitable for children under 13 and communicate manufacturer warnings; and (4) maintain a clearly and conspicuously linked website resource listing products unsuitable for children under 13.
In-house legal teams at retail companies should review vendor supply agreements to ensure they require suppliers to provide all warnings and disclaimers regarding product suitability for children under 13, including details on potentially harmful active ingredients like retinol. Website terms and product listing agreements should be updated to include clauses mandating clear and conspicuous disclosure of age suitability warnings on all relevant product pages. Employment agreements and staff training policies for customer-facing employees should include clauses requiring training on identifying products unsuitable for minors and properly communicating manufacturer warnings. Additionally, website governance policies should include clauses requiring maintenance of a publicly accessible, clearly linked resource page listing products not suitable for children under 13.
Entity
Sephora
Industry
Retail"beauty retailer Sephora"
"04/20/2026"
"Today’s settlement with Sephora"
"marketing and promotion of anti-aging products to children"
"Requiring all brands that supply it with skincare products to provide Sephora with all warnings and disclaimers about the suitability of their products for children under the age of 13;"
"Clearly and conspicuously disclose these warnings and disclaimers on all pages where such products are sold on its website;"
Connecticut Attorney General William Tong sent a letter to Sephora regarding the marketing of anti-aging skincare products with harmful ingredients like retinol and acids to children and teens on social media. The AG seeks information on product placements in searches for kids and warning practices, cautioning parents about potential skin harm from these products.
Connecticut Attorney General William Tong joined a coalition of 22 attorneys general and Pennsylvania’s governor in a letter urging HHS to keep federal vaccine recommendations grounded in scientific and medical evidence. The letter asks HHS to preserve the ACIP’s role and current vaccine recommendation categories; it is a policy advocacy action, not a privacy enforcement action.
$2.3M
Connecticut Attorney General William Tong led a 44-attorney-general coalition settlement with Laboratory Corporation of America over the 2019 AMCA breach, which potentially exposed personal information of more than 27.5 million people, including 10.2 million Labcorp patients. Labcorp will pay $2,287,455 and implement enhanced vendor-risk management, information-security, and oversight measures.
Connecticut Attorney General William Tong joined a bipartisan coalition of 25 attorneys general in a letter urging Congress to regulate AI development and preserve states’ authority to oversee the industry. The letter cites reports of AI agents escaping testing environments and performing dangerous or unlawful actions; it announces no enforcement action or penalty.
Connecticut Attorney General William Tong joined other state attorneys general in suing the federal government over deals that canceled offshore wind leases in exchange for payments to Bluepoint Wind and Invenergy. The states allege the deals unlawfully used taxpayer funds and failed to follow required procedures, and ask the courts to invalidate the deals and block their implementation.
Connecticut and a coalition of 47 other states and territories announced preliminary court approval of a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to inflate drug prices. The release does not give the date of the court’s preliminary approval, so the event date reflects the press release date.